Spots Global Cancer Trial Database for metastatic clear cell renal cell carcinoma
Every month we try and update this database with for metastatic clear cell renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer | NCT06059014 | Metastatic Clea... | 177Lu-PSMA-1 (r... | 18 Years - | Centre Leon Berard | |
| High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | NCT01896271 | Metastatic Clea... | IL-2 Stereotactic Ab... | 18 Years - 99 Years | University of Texas Southwestern Medical Center | |
| Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery | NCT04370509 | Metastatic Clea... Recurrent Clear... Stage III Renal... Stage IV Renal ... Clear Cell Rena... | Axitinib (VEGF-... Cytoreductive N... Metastasectomy ... Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma | NCT01510119 | Metastatic Clea... | Hydroxychloroqu... RAD001 | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | NCT04388852 | Aggressive Vari... Castration-Resi... Metastatic Clea... Metastatic Mali... Metastatic Pros... Metastatic Urot... Stage IV Prosta... Stage IV Renal ... Stage IVA Prost... Stage IVB Prost... | Ipilimumab Valemetostat | 18 Years - | M.D. Anderson Cancer Center | |
| High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | NCT01896271 | Metastatic Clea... | IL-2 Stereotactic Ab... | 18 Years - 99 Years | University of Texas Southwestern Medical Center | |
| Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03260504 | Advanced Clear ... Stage III Renal... Stage IV Renal ... Metastatic Clea... | Aldesleukin Pembrolizumab | 18 Years - | University of Washington | |
| Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma | NCT02781506 | Metastatic Clea... | Nivolumab SAbR | 18 Years - 100 Years | University of Texas Southwestern Medical Center | |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer | NCT06059014 | Metastatic Clea... | 177Lu-PSMA-1 (r... | 18 Years - | Centre Leon Berard | |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03260504 | Advanced Clear ... Stage III Renal... Stage IV Renal ... Metastatic Clea... | Aldesleukin Pembrolizumab | 18 Years - | University of Washington | |
| Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer | NCT02002312 | Metastatic Clea... | Lu-177-DOTA-gir... | 18 Years - | Radboud University Medical Center | |
| Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | NCT05361720 | Advanced Clear ... Metastatic Clea... Stage III Renal... Stage IV Renal ... | Cabozantinib Ipilimumab Nivolumab | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery | NCT03334409 | Clear Cell Rena... Metastatic Clea... Stage III Renal... Stage IV Renal ... Unresectable Re... | Ascorbic Acid Pazopanib Hydro... | 18 Years - | Academic and Community Cancer Research United | |
| Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | NCT05012371 | Advanced Clear ... Metastatic Clea... Stage III Renal... Stage IV Renal ... | Cabozantinib Everolimus Lenvatinib Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | NCT04510597 | Metastatic Clea... Metastatic Rena... Stage IV Renal ... | Cytoreductive N... Active Comparat... | 18 Years - | SWOG Cancer Research Network | |
| A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | NCT01391130 | Metastatic Clea... | LY2510924 Sunitinib | 18 Years - | Eli Lilly and Company | |
| A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | NCT01391130 | Metastatic Clea... | LY2510924 Sunitinib | 18 Years - | Eli Lilly and Company | |
| Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03260504 | Advanced Clear ... Stage III Renal... Stage IV Renal ... Metastatic Clea... | Aldesleukin Pembrolizumab | 18 Years - | University of Washington | |
| Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma | NCT02848768 | Metastatic Clea... | Sunitinib | 18 Years - | Rennes University Hospital | |
| Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | NCT04904302 | Advanced Clear ... Metastatic Clea... Stage IV Renal ... | Nivolumab Quality-of-Life... Questionnaire A... Sitravatinib | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
